Clinical Trial

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

Study acronym: ACCESS
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with borderline resectable stage III Non-small Cell Lung Cancer (NSCLC) (ACCESS)
Trial Details
NCT Number NCT06998719
Lead Sponsor Bi Nan
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma
Enrollment 80 participants
Start Date 2025-07
Primary Completion 2026-05 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-31